The Food and Drug Administration is considering pulling its authorization of Pfizer’s COVID-19 vaccine for healthy children ...

Research and Development Expenses-- $4,700,000 compared to $5,600,000 during the prior year comparable period. Kodiak PCR ...

AstraZeneca’s FluMist, the only nasal spray flu vaccine in the US that has been approved by the US Food and Drug ...

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

After a gunman opened fire on the Centers for Disease Control and Prevention (CDC) campus in Atlanta last week -- forcing ...

With the latest COVID-19 surge, information on testing and vaccinations for those who are uninsured is becoming hard to find.

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-yearInvivyd’s target of near-term profitability (1H 2025) was not met but remains ...

Diagnostics' progress on their PCR platform, with key trials in 2025 and commercialization plans by 2026, targeting U.S. and global markets.

After a gunman opened fire on the Centers for Disease Control and Prevention (CDC) campus in Atlanta last week -- forcing hundreds into lockdown, hitting six buildings and killing a police officer -- ...

Dr Vinay Prasad will return to head the FDA’s Center for Biologics Evaluation and Research less than 2 weeks after being ousted.